REG - Nuformix PLC - Result of General Meeting

NuformixAnnouncement

04/11/2024 10:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241104:nRSD8241Ka&default-theme=true

RNS Number : 8241K  Nuformix PLC  04 November 2024

4 November 2024

 

Nuformix plc

 

("Nuformix" or the "Company")

 

Result of General Meeting

 

Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, announces that at
the General Meeting of the Company held earlier today all resolutions put to
shareholders were duly passed and approved by way of a show of hands.  The
proxies received ahead of the General Meeting, are reported below:

 

     Resolution                                                 Ordinary/ Special  For                   Against              Total votes cast
                                                                                   No. of votes  %       No. of votes  %
 1   Subdivision of the ordinary shares                         Ordinary           164,225,020   98.00%  3,356,013     2.00%  167,581,033

 2   To authorise the directors to allot shares                 Ordinary           163,856,186   97.99%  3,361,741     2.01%  167,217,927

 3   To authorise the directors to disapply pre-emption rights  Special            163,856,186   98.04%  3,273,557     1.96%  167,129,743

 4   Amendment of the Company's Articles of Association         Special            163,856,186   98.04%  3,273,557     1.96%  167,129,743

A vote withheld is not a vote in law and is not counted in the calculation of
votes validly cast for or against a resolution.

 

Full details of the Resolutions are contained in the Notice of General Meeting
which is available, appended to the Prospectus, on the Company's website at:
https://nuformix.com/document-center/ (https://nuformix.com/document-center/)

 

Following the passing of the Resolutions at the General Meeting, the expected
timetable of events remains the same as documented in the Prospectus and is as
follows:

 

                                                                              2024
 Record Date for the Capital Reorganisation                                   6.00 p.m. on 4 November
 Admission of New Ordinary Shares effective and commencement of dealing       8.00 a.m. on 5 November

 Expected date for CREST accounts to be credited                              5 November
 Despatch of definitive certificates (where applicable) expected by no later  11 November
 than

 

Admission and Total Voting Rights

 

An application has been made to the London Stock Exchange for the 600,000,000
New Ordinary Shares, to be issued pursuant to the conditional £300,000
fundraise announced on 20 September 2024, to be admitted to the equity shares
(transition) category of the Financial Conduct Authority's Official List and
to trading on the Main Market of the London Stock Exchange ("Admission").  It
is expected that Admission and unconditional dealings in the New Ordinary
Shares will commence on the London Stock Exchange at 8.00 a.m. on 5 November
2024.

 

Following Admission of the New Ordinary Shares, the total number of Ordinary
Shares in issue will be 1,419,309,368, each with one voting right.  The
Company does not hold any rights in treasury.  The total voting rights figure
is therefore 1,419,309,368 and can be used by shareholders as the denominator
for the calculations by which they will determine whether they are required to
notify their interest in, or a change of their interest in, the Company under
the Disclosure Guidance and Transparency Rules of the Financial Conduct
Authority.

 

Terms used in this announcement shall, unless the context otherwise requires,
be as defined in the Prospectus published by the Company on 16 October 2024.

 

Enquiries:

 

 Nuformix plc
 Dr Dan Gooding, Executive Director  Via IFC Advisory

 CMC Markets
 Douglas Crippen                     +44 (0) 20 3003 8632

 IFC Advisory Limited
 Tim Metcalfe                        +44 (0) 20 3934 6630

 Zach Cohen                          nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities.  Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMMZMGMGDVGDZM